阿托伐他汀对急性肺动脉栓塞患者血清C-反应蛋白的影响

Effect of Atorvastatin on C-reactive protein in patients with acute pulmonary embolism

目的探讨阿托伐他汀早期干预对急性肺动脉血栓栓塞患者血清C-反应蛋白的影响。方法选取2010年10月～2012年12月确诊为急性肺动脉血栓栓塞患者58例。均给予常规治疗15 d。将其分为两组。对照组(n=32)给予常规治疗,阿托伐他汀组(n=26)在常规治疗基础上加用阿托伐他汀20 mg。比较两组血气分析、C-反应蛋白表达水平、右室内径、肺动脉压。应用SPSS 11.0统计软件进行统计学分析,以P<0.05为差异有统计学意义。结果阿托伐他汀组血气分析中动脉血氧分压(PaO2)在入院后6 h、3 d、15 d均略高于对照组[(83.25±10.01)mm Hg比(77.40±12.11)mm Hg,(90.34±4.01)mm Hg比(86.16±4.11)mm Hg,(89.59±3.05)mm Hg比(93.63±3.55)mm Hg,1 mm Hg=0.133 kPa],差异有统计学意义(P<0.05)。阿托伐他汀组C-反应蛋白表达水平在入院后6 h、15 d低于对照组[(20.53±7.66)μg/L比(25.50±7.91)μg/L,(11.58±5.61)μg/L比(15.36±6.72)μg/L],差异有统计学意义(P<0.05)。治疗15 d阿托伐他汀组右室内径[(23.1±5.5)mm比(28.4±6.3)mm]、肺动脉压平均值[(30.4±6.3)mm Hg比(36.6±8.5)mm Hg]低于对照组,差异有统计学意义(P<0.05)。结论常规治疗加用阿托伐他汀可进一步降低急性肺动脉栓塞患者C-反应蛋白表达水平,改善低氧血症,降低肺动脉压,可成为急性肺动脉栓塞患者辅助治疗的选择。

Objective To study the effect of Atorvastatin on C-reactive protein（CRP） in acute pulmonary embolism（APE） patients.Methods Patients confirmed acute pulmonary embolism were enrolled from October 2010 to December 2012.All patients were divided into two groups.Control group（n = 32） was only given conventional therapy;Atorvastatin group（n = 26） was given Atorvastatin 20 mg on basis of conventional therapy.Both groups accepted conventional therapy for 15 days.Blood gas profiles,echocardiography results and serum level of CRP were recorded and compared.The statistical significance of the change in different models were analyzed by SPSS 11.0 statistics software.A value of P〈0.05 was accepted as statistically significant.Results The level of PaO2 6 h,3 d,15 d after admission in Atorvastatin group was higher than that in control group [（83.25±10.01） mm Hg vs（77.40±12.11） mm Hg,（90.34±4.01） mm Hg vs（86.16±4.11） mm Hg,（89.59±3.05） mm Hg vs（93.63±3.55） mm Hg,1 mm Hg=0.133 kPa],with significant differences（P〈0.05）.Serum level of CRP,right ventricular diameter and pulmonary artery pressure at 6 h,15 d after ad mission in Atorvastatin group was lower than that in control group,as [（20.53 ±7.66） μg/L vs（25.50 ±7.91） μg/L,（11.58±5.61） μg/L vs（15.36±6.72） μg/L;（23.1±5.5） mm vs（28.4±6.3） mm,（30.4±6.3） mm Hg vs（36.6±8.5） mm Hg],with significant differences（P〈0.05）.Conclusion On the basis of conventional therapy,Atorvastatin makes further effect on reducing serum level of CRP and pulmonary artery pressure,improving hypoxemia.Perhaps Atorvastatin can become an adjunctive therapy choice for acute pulmonary embolism patients.